Treatment of the special patient with schizophrenia

por Conley, Robert R., Kelly, Deanna L.
Publicado 2001

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

por Peng, Xiaomei, Ascher-Svanum, Haya, Faries, Douglas, Conley, Robert R, Schuh, Kory J
Publicado 2011

Dopamine Pathology in Schizophrenia: Analysis of Total and Phosphorylated Tyrosine Hydroxylase in the Substantia Nigra

por Perez-Costas, Emma, Melendez-Ferro, Miguel, Rice, Matthew W., Conley, Robert R., Roberts, Rosalinda C.
Publicado 2012

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis

por Ye, Wenyu, Ascher-Svanum, Haya, Tanji, Yuka, Flynn, Jennifer A, Takahashi, Michihiro, Conley, Robert R
Publicado 2012

The cost of relapse and the predictors of relapse in the treatment of schizophrenia

por Ascher-Svanum, Haya, Zhu, Baojin, Faries, Douglas E, Salkever, David, Slade, Eric P, Peng, Xiaomei, Conley, Robert R
Publicado 2010

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

por Furiak, Nicolas M, Ascher-Svanum, Haya, Klein, Robert W, Smolen, Lee J, Lawson, Anthony H, Conley, Robert R, Culler, Steven D
Publicado 2009

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia

por Ruberg, Stephen J, Chen, Lei, Stauffer, Virginia, Ascher-Svanum, Haya, Kollack-Walker, Sara, Conley, Robert R, Kane, John, Kinon, Bruce J
Publicado 2011

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment

por Dodick, David W, Goadsby, Peter J, Lucas, Christian, Jensen, Rigmor, Bardos, Jennifer N, Martinez, James M, Zhou, Chunmei, Aurora, Sheena K, Yang, Jyun Yan, Conley, Robert R, Oakes, Tina
Publicado 2020